Charterhouse Capital Partners
 | |
| Company type | Limited liability partnership |
|---|---|
| Industry | Private equity |
| Founded | 1934 |
| Headquarters | London, England |
| Products | Private equity funds, Leveraged buyouts |
| Website | www.charterhouse.co.uk |
Charterhouse Capital Partners is a London based private equity investment firm focused on investing in European mid-market companies valued between €200m and €1.5bn.[1] The company targets investments across the services, healthcare, specialised industrials and consumer sectors.[2]
History
Founded in 1934,[3] Charterhouse Capital Partners is one of Europe’s oldest private equity firms.[4] The firm's predecessors, then a division of Charterhouse Bank, began raising third party equity in 1976.[3] In June 2001, the firm's management completed a management buyout from HSBC to become an independent investment firm.[5]
Notable investment activity
In 2009, Charterhouse acquired Wood Mackenzie, selling its stake to Hellman & Friedman in 2012.[6]
In 2010, the company acquired Deb Group, a skincare product group, and sold its stake in 2015 to SC Johnson, reportedly earning a return of over 2.5x.[7]
In 2010, they acquired Card Factory, exiting its stake in 2015.[8]
In 2011, the company acquired ERM, and in 2015, sold its stake to Omers in a deal valued at $1.7 billion.[9]
In 2011, they acquired Webhelp, selling the company to KKR in 2015.[10]
In 2013, Charterhouse acquired Doc Generici, an Italian pharmaceutical business, selling in 2016 to CVC Capital Partners.[11]
In 2013, the company acquired Armacell in a €520 million deal and, in 2015, sold to a Blackstone led partnership in a deal valued at €960 million.[12]
In 2016, the company acquired Cooper, a provider of generalist over-the-counter (OTC) self-care pharmaceuticals, and in March 2021 sold a majority stake to CVC.[13]
In 2017, the company acquired a majority stake in SERB, a Brussels headquartered specialty pharmaceuticals company.[14]
In 2018, they acquired a majority stake in Siaci Saint Honore (SSH), a B2B insurance broker, and sold in July 2021 to a consortium led by Burrus Group.[15]
In 2015, Charterhouse acquired Mirion Technologies, a radiation detection provider, for $750 million, and in June 2021, Mirion announced it would go public after merging with a Goldman Sachs backed SPAC in a deal valued at $2.6 billion.[16]
References
- ^ European buyout firms seek more than $80bn in crowded fundraising market Private Equity News
- ^ Charterhouse eyes lower flagship target amid mid-market push for €2.5bn Fund XIPrivate Equity International
- ^ a b Jowett, Paul (2011). Private Equity: The German Experience. Palgrave Macmillan. p. 427. ISBN 978-1-349-35942-4.
- ^ Porter, Kiel; Willmer, Sabrina (12 November 2013). "Charterhouse Heirs Struggle to Maintain Bonnyman Legacy". Archived from the original on 18 January 2016. Retrieved 18 January 2016.
- ^ "Charterhouse sticks to its winning formula". Financial News. 12 January 2009. Retrieved 13 April 2017.
- ^ Charterhouse buys WoodMac for £553mEvening Standard
- ^ Charterhouse nets more than 2.5x on Deb GroupPrivate Equity International
- ^ Charterhouse scores 5.25x on Card FactoryPrivate Equity International
- ^ Charterhouse Capital sells ERM stake to Omers in $1.7 bln deal Reuters
- ^ Charterhouse Triples Its Money on Webhelp Exit Private Equity News
- ^ CVC acquires Doc Generici from Charterhouse Unquote
- ^ Charterhouse sells Armacell to Blackstone-led partnership Reuters
- ^ Charterhouse in exclusive talks to sell control of French drugmaker Cooper Reuters
- ^ Charterhouse Buys Belgium-Based Drug Company SERB Private Equity News
- ^ Charterhouse to exit Siaci Saint Honoré to OTPP et al. Unquote
- ^ Goldman-backed SPAC to take Mirion Tech public in $2.6 bln deal Reuters
External links
 | This article about a private equity or venture capital firm based in the United Kingdom is a stub. You can help Wikipedia by expanding it. |